PROCEDURES · HEALTH
Biologic infusion: uses, how it is given, recovery and risks
A biologic infusion delivers a biologic medication through a vein, such as infliximab, which blocks TNF, a substance involved in inflammation, and is used for conditions such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. A rheumatologist prescribes and monitors treatment, and the infusions are given at an outpatient infusion center.
Starting intravenous biologic treatment raises many questions, and it helps to arrive at your first session knowing what will happen.
Schedule an evaluationWhat it is
Immunobiologics, also called biologic medications, are proteins used as medicines that block or regulate cells and substances involved in inflammation; the first widely used ones targeted TNF. In chronic autoimmune diseases that have not responded to other treatments, biologic therapy may relieve symptoms and, in some cases, bring the disease into remission. Some can be injected under the skin; infliximab, for example, is available in both intravenous and under-the-skin forms.
For rheumatoid arthritis, they are generally added when methotrexate, used initially, has not controlled the disease sufficiently after 3 to 6 months.
Purpose
- Rheumatoid arthritis that has not responded sufficiently to initial treatment with methotrexate after 3 to 6 months.
- Ankylosing spondylitis, based on the rheumatologist's evaluation.
- Psoriatic arthritis: medications such as infliximab have shown benefits for the various manifestations of the disease and in slowing progressive joint damage.
- Other inflammatory diseases, such as Crohn's disease, ulcerative colitis and plaque psoriasis, based on the specialist's evaluation.
Related conditions
How it is done
The medication enters through the vein slowly, at a controlled rate, which the team can reduce if any symptoms appear. The team monitors you throughout the infusion. For people who have had a reaction, the doctor may prescribe medications before future infusions.
The infusion is given at an outpatient infusion center, without hospitalization. The interval between infusions follows the schedule set by the rheumatologist. The team pays particular attention during administration, when reactions tend to occur, usually in the first few minutes.
Preparation
- Screening for latent tuberculosis before starting, with a chest X-ray, a skin test (PPD) and a blood test (IGRA), depending on the case.
- Hepatitis B, hepatitis C and HIV tests before starting.
- Bring vaccinations up to date, if possible well before starting treatment.
- Tell the team if you have a fever or an infection on the day of the infusion. The doctor gives you instructions for your case.
Tests commonly ordered
Hepatitis B tests
From R$ 31.93 (≈ US$ 6, estimated) Estimated value in US dollars at the tourist exchange rate, updated daily; payment is made in Brazilian reais.
Hepatitis C test
From R$ 52.08 (≈ US$ 10, estimated)
HIV test
Starting at R$ 33.00 (≈ US$ 6, estimated)
Complete blood count
Starting at R$ 11.63 (≈ US$ 3, estimated)
Self-pay prices updated on November 17, 2026. Your doctor determines which tests make sense for your case.
Recovery
The rheumatologist assesses your response to treatment during appointments.
Watch for signs of infection, keep up with appointments and tell any doctor or dentist that you take a biologic medication, especially before surgery: the medication is often paused before scheduled surgery, but this decision is individual and is made by the doctor.
Risks and precautions
- A reaction during the infusion, such as itching, redness, chills, fever or a drop in blood pressure.
- Increased risk of infections, because the medication may reduce some of the body's defenses.
- Reactivation of tuberculosis in people with latent infection.
- An infusion reaction that may also occur after administration, not just during it.
- Liver injury caused by the medication, which has been observed with TNF inhibitors and is monitored by the doctor.
When to go to the emergency department after the procedure
- Shortness of breath, throat irritation, raised patches on the skin or facial swelling during the infusion: tell the team right away. If these occur afterward, go to the emergency room or call SAMU (Brazil's emergency medical service) at 192.
- Signs of infection that do not improve or get worse: seek medical care.
- New symptoms that appear after the infusion: tell your doctor.
In an emergency, call 192 (SAMU, Brazil's emergency medical service) or go to the nearest emergency room.
Alternatives
Depending on the disease and your case, other options are available: other biologics, including biosimilars, synthetic disease-modifying medications such as methotrexate, and JAK inhibitors. The choice is made through a discussion between you and your rheumatologist.
Frequently asked questions
Does a biologic infusion hurt?
If you feel anything unusual during the infusion, tell the team right away.
How long does each session take?
For infliximab, the infusion generally takes 2 to 4 hours; the exact time depends on the case and the medication. Allow plenty of time and bring something to read.
Will I need a hospital stay?
No. The infusion is given at an outpatient infusion center, without hospitalization.
Can I get vaccinated during treatment?
Inactivated vaccines are considered safe, but the response to them may be lower; live-virus vaccines, such as the yellow fever vaccine, are contraindicated. Always check with your rheumatologist before getting vaccinated.
Can I work as usual?
Talk to your rheumatologist about your routine on infusion days.
Does my health plan cover it?
It depends on your health plan and contract. Our team confirms coverage with you before scheduling.
Can an online consultation help?
An online consultation helps provide guidance, review test results and follow up between sessions. The evaluation and infusions take place in person in São Paulo.
Where we see patients
References
- Lecluse LL, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008.
- Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center. J Manag Care Spec Pharm. 2018.
- Mease PJ. Biologic Therapy for Psoriatic Arthritis. Rheum Dis Clin North Am. 2015.
- Hall V, Johnson D, Torresi J. Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. J Travel Med. 2018.
- Huguet JM, et al. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines. 2022.
- EULAR. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026.
- Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol. 2006.
- Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion. Adv Rheumatol. 2018.
- No post-infusion reactions after infliximab or vedolizumab. Dan Med J. 2025.
- Sincić BM, Vince A. Screening for opportunistic infections and vaccination before introduction of biologic therapy. Acta Med Croatica. 2013.
- Mancuso F, et al. Perioperative Management of Biologic and Targeted Synthetic DMARDs in Orthopedic Surgery: Balancing Infection Risk and Disease Control. Microorganisms. 2026.
- Cantini F, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015.
- Dharmaraj R, et al. Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease. Children (Basel). 2024.
- Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. Hepatol Commun. 2020.
- Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adhere. 2017.
This content is informational and does not replace a consultation.
Updated on